Home/Pipeline/Second-generation telomere targeting agents

Second-generation telomere targeting agents

Cancer

Pre-clinical/ResearchDiscovery and development

Key Facts

Indication

Cancer

Phase

Pre-clinical/Research

Status

Discovery and development

Company

MAIA Biotechnology

About MAIA Biotechnology

MAIA Biotechnology is a targeted therapy and immuno-oncology company focused on developing first-in-class drugs with novel mechanisms of action to improve and extend the lives of cancer patients. Its core achievement is the advancement of its lead asset, ateganosine (THIO), a dual-mechanism telomere-targeting agent, into Phase 2 clinical trials. The company's strategy leverages a proprietary platform of telomere biology to induce direct cancer cell death and generate an immunogenic response, differentiating it from conventional therapies. MAIA operates as a public entity, trading on the NYSE American exchange, and is positioned within the high-potential RNA & Gene Therapy sector.

View full company profile

Therapeutic Areas

Oncology

Other Cancer Drugs

Drug	Company	Phase	Status
Not Specified (Oncology Focus)	Narwhal Bio	Pre-clinical	Active
EDM Platform for Genetic Medicine	Coastar Therapeutics	Pre-clinical	Platform Development
CO-1	Caedo Oncology	Pre-clinical	Active R&D
Anti-CD99 monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Anti-HLA class I monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Triapine®	Nanopharmaceutics	Clinical	Active
Ammonium Tetrathiomolybdate	Nanopharmaceutics	Clinical	Active
Aza-TdC	Nanopharmaceutics	Clinical	Active
Undisclosed Oncology Program(s)	Cell BioEngines	Phase 1	Active
No-alpha IL-2 Mutein	SarcoMed USA	Pre-clinical	Active
PMIS Therapeutic	NaturemiRI	Preclinical/Clinical (unspecified)	Active
AUM302 (formerly IBL-302)	Inflection Biosciences	Pre-clinical (partnered)	Active